Literature DB >> 35403137

Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Ulrich H Weidle1, Fabian Birzele2.   

Abstract

Progressive and metastatic bladder cancer remain difficult to treat. In this review, we critique seven up-regulated and 25 down-regulated microRNAs in order to identify new therapeutic entities and corresponding targets. These microRNAs were selected with respect to their efficacy in bladder cancer-related preclinical in vivo models. MicroRNAs and related targets interfering with chemoresistance, cell-cycle, signaling, apoptosis, autophagy, transcription factor modulation, epigenetic modification and metabolism are described. In addition, we highlight microRNAs targeting transmembrane receptors and secreted factors. We discuss druggability issues for the identified targets. Copyright 2021, International Institute of Anticancer Research.

Entities:  

Keywords:  Apoptosis; bladder cancer-related targets; cell cycle; epigenetic modifiers; invasion and proliferation; migration; orthotopic and xenograft models; review; tumor growth and metastasis

Year:  2021        PMID: 35403137      PMCID: PMC8988954          DOI: 10.21873/cdp.10033

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  202 in total

1.  miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer.

Authors:  Qiangqiang Ge; Mengxin Lu; Lingao Ju; Kaiyu Qian; Gang Wang; Chin-Lee Wu; Xuefeng Liu; Yu Xiao; Xinghuan Wang
Journal:  Int J Cancer       Date:  2019-01-12       Impact factor: 7.396

2.  Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer.

Authors:  Michela de Martino; Shahrokh F Shariat; Sebastian L Hofbauer; Ilaria Lucca; Christopher Taus; Helene G Wiener; Andrea Haitel; Martin Susani; Tobias Klatte
Journal:  World J Urol       Date:  2014-02-23       Impact factor: 4.226

Review 3.  ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.

Authors:  Jianbiao Zhou; Yvonne Ng; Wee-Joo Chng
Journal:  Cell Mol Life Sci       Date:  2018-07-31       Impact factor: 9.261

Review 4.  mTOR inhibitors in urinary bladder cancer.

Authors:  R Pinto-Leite; R Arantes-Rodrigues; Nuno Sousa; P A Oliveira; L Santos
Journal:  Tumour Biol       Date:  2016-05-27

5.  DEDD, a novel tumor repressor, reverses epithelial-mesenchymal transition by activating selective autophagy.

Authors:  Qi Lv; Fang Hua; Zhuo-Wei Hu
Journal:  Autophagy       Date:  2012-08-09       Impact factor: 16.016

Review 6.  Targeting survivin in cancer.

Authors:  Dario C Altieri
Journal:  Cancer Lett       Date:  2012-03-09       Impact factor: 8.679

Review 7.  Mechanisms of lymphatic metastasis.

Authors:  Sinem Karaman; Michael Detmar
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

8.  PTTG1 regulated by miR-146a-3p promotes bladder cancer migration, invasion, metastasis and growth.

Authors:  Wei Xiang; Xinchao Wu; Chao Huang; Miao Wang; Xian Zhao; Gang Luo; Yawei Li; Guosong Jiang; Xingyuan Xiao; Fuqing Zeng
Journal:  Oncotarget       Date:  2017-01-03

9.  Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.

Authors:  Aaron Mobley; Shizhen Zhang; Jolanta Bondaruk; Yan Wang; Tadeusz Majewski; Nancy P Caraway; Li Huang; Einav Shoshan; Guermarie Velazquez-Torres; Giovanni Nitti; Sangkyou Lee; June Goo Lee; Enrique Fuentes-Mattei; Daniel Willis; Li Zhang; Charles C Guo; Hui Yao; Keith Baggerly; Yair Lotan; Seth P Lerner; Colin Dinney; David McConkey; Menashe Bar-Eli; Bogdan Czerniak
Journal:  Sci Rep       Date:  2017-01-19       Impact factor: 4.379

Review 10.  Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.

Authors:  Chiara Casadei; Nazli Dizman; Giuseppe Schepisi; Maria Concetta Cursano; Umberto Basso; Daniele Santini; Sumanta K Pal; Ugo De Giorgi
Journal:  Ther Adv Med Oncol       Date:  2019-11-25       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.